AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01222143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVE-HiDAC
Description: NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12.~During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10.
Study NCT01222143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study.~During induction, nilotinib will be given orally on Days 1-12.~During consolidation, nilotinib will be given orally on Days 1-10.
Study NCT03585101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir
Description: Daily fixed-dose combination (FDC) elbasvir (EBR) (50 mg)/grazoprevir (GZR) (100 mg) for 12 weeks
Study NCT01606696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Higher intensity interval training.
Study NCT01606696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intensity non-interval training
Description: Standard intensity non-interval training.
Study NCT03399162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREHAB Workshop
Description: PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
Study NCT03399162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREHAB Workshop
Description: PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
Study NCT03399162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREHAB Exercise Program
Description: An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
Study NCT01655602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trichophytic closure upper edge trimming
Description: 'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
Study NCT01655602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trichophytic closure lower edge trimming
Description: 'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
Study NCT01655602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trichophytic closure both edge trimming
Description: 'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
Study NCT03557216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical and occult blood test
Description: A test for fecal occult blood looks for blood in your feces. It can be a sign of a problem in the digestive system, such as a polyp or cancer in the colon.
Study NCT03557216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin test
Description: Calprotectin is a protein released by neutrophils. When there is inflammation in the colon, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. This test measures the level of calprotectin in stool as a way to detect inflammation and lesions in the colon.
Study NCT03015610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: commercially available lansoprazole
Description: these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily lansoprazole for 24 weeks
Study NCT03015610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
Study NCT04025411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Visual Simulation 3 (IVS3) device
Description: Visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).~The patient looks on a screen in front of him, mirroring the movements made by his healthy hand, while attempting to perform the same movement with his paretic hand.
Study NCT04025411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional Mirror Therapy (TM)
Description: Simulation with the traditional Mirror Therapy (TM) will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).
Study NCT01183013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg / Pioglitazone 30 mg FDC
Description: Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
Study NCT01183013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin 5mg
Description: Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
Study NCT01183013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg / Pioglitazone 15 mg FDC
Description: Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
Study NCT04025411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) will be performed during the 1st, 6th, 11th, 16th and 20th session of their programme will be made in order to evaluate brain activity.
Study NCT04025411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) will be performed during the 1st, 6th, 11th, 16th and 20th session of their programme will be made in order to evaluate brain activity.
Study NCT01436877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of Temporary Implantable Nitinol Device (TIND)
Description: Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
Study NCT04434469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7297089
Description: RO7297089 will be given via intravenous (IV) infusion
Study NCT00254800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and levonorgestrel; exenatide
Description: Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
Study NCT02825758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ZestiVits
Description: The study product is a low-carbohydrate, orange flavour, vitamin, mineral and trace element (micronutrient) supplement for use in ketogenic and restricted therapeutic diets, for children aged from 11 years of age and adults.~The recommended dosage of the study product for each subject will be determined and prescribed by a dietitian. This will be based on individual requirements for micronutrient supplementation.
Study NCT02295020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment only
Description: Standard treatment such as NSAIDs and injections
Study NCT02295020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment only
Description: Standard treatment such as NSAIDs and injections
Study NCT02295020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard treatment plus Bioskin Ten-7 knee brace
Description: Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.
Study NCT03776110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT9906 PR tablet
Description: 40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)
Study NCT03776110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching 40 mg GRT9906 PR tablet
Study NCT02873962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * Bevacizumab will be given intravenously at a pre-determined dosage~* One dose reduction will be allowed for Bevacizumab
Study NCT02873962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage.~* No dose reductions or escalations will be allowed for Nivolumab
Study NCT02873962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: * Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage.~* Up to three dose reductions will be allowed for Rucaparib (depending on cohort).
Study NCT02113098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill, ankle load
Description: The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
Study NCT02113098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
Study NCT02963428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy.
Study NCT00562302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Seal Plug
Description: Deployment of the Bio-Seal plug in needle track
Study NCT03702075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-administered program
Description: One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
Study NCT03388645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^6.3 PFU of RSV A2
Description: Each adult volunteer will receive a single intranasal inoculation of 10\^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
Study NCT03388645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^7 PFU of RSV A2
Description: Each adult volunteer will receive a single intranasal inoculation of 10\^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
Study NCT00119691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
Study NCT00119691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
Study NCT01986361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen
Description: A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
Study NCT01986361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
Study NCT03465020 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Safety and efficacy outcomes of patients on different treatments
Study NCT01710163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
Study NCT01710163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
Study NCT00267696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
Study NCT00267696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
Study NCT00267696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02281396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old
Description: Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
Study NCT02281396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old
Description: Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
Study NCT02394496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
Study NCT02394496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1500mg (TBD) O.S. qd
Study NCT02281396 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)
Description: Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
Study NCT02281396 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)
Description: Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
Study NCT02394496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: as indicated in the Summary Product Characteristic
Study NCT02394496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Lapatinib
Description: 1500mg (TBD) O.S. qd
Study NCT03666936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social-health care intervention
Description: Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
Study NCT03968003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.This study evaluates the changes of gut microbiota composition and diversity, body weight, body fat, SCFAs, plasma amino acids, satiety hormones (PYY and GLP-1), Inflammatory cytokines (IL-1β, TNF-α and IL-6) after 6-month studied period
Study NCT03968003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.This study evaluates the changes of gut microbiota composition and diversity, body weight, body fat, SCFAs, plasma amino acids, satiety hormones (PYY and GLP-1), Inflammatory cytokines (IL-1β, TNF-α and IL-6) after 6-month studied period
Study NCT03968003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.This study evaluates the changes of gut microbiota composition and diversity, body weight, body fat, SCFAs, plasma amino acids, satiety hormones (PYY and GLP-1), Inflammatory cytokines (IL-1β, TNF-α and IL-6) after 6-month studied period
Study NCT02440984 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonic biopsies during endoscopy
Description: eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
Study NCT00734110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P.F.C. Sigma Total Knee System
Description: An orthopaedic implant for total knee replacement
Study NCT04704492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: SM03
Description: Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
Study NCT03544099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg Intravenous Solution
Study NCT03748810 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin 25 mg once daily add on the background OADs for 3 years
Study NCT03748810 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin
Description: Dapagliflozin 25 mg once daily add on the background OADs for 3 years
Study NCT00863473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment with LCP
Study NCT03186274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Group Session
Description: Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.
Study NCT03186274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CELA Session
Description: Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
Study NCT02636231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endostatins
Description: Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
Study NCT02636231 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT is to give GTV 60Gy in 27 fractions.
Study NCT02636231 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT is to give GTV 60Gy in 27 fractions.
Study NCT03153475 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ATTUNE Revision Knee System in Revision Total Knee Arthroplasty
Description: Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
Study NCT01878422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: FOLFIRI or FOLFOX + Bevacizumab
Description: Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
Study NCT01878422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B: FOLFIRI or FOLFOX
Description: Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
Study NCT01878422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
Description: Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
Study NCT01878422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
Description: Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB